Results 111 to 120 of about 43,711 (206)

Muscarinic agonists for schizophrenia: Bridging preclinical evidence and clinical enthusiasm

British Journal of Pharmacology, Volume 183, Issue 19, Page 5701-5731, October 2026.
Abstract Antipsychotic drugs targeting dopamine receptors have been used to treat schizophrenia for decades, primarily alleviating positive symptoms such as hallucinations and delusions. However, they provide limited benefit for cognitive and negative symptoms—major contributors to poor outcomes—and are frequently associated with significant side ...
Brian J. Morris, Judith A. Pratt
wiley   +1 more source

[Value of the determination of erythrocyte haloperidol ketone reductase activity in the evaluation of haloperidol therapy]

, 1994
International audienceSerum levels of haloperidol and reduced haloperidol as well as the reduced haloperidol/haloperidol ratios were determined in nine acute schizophrenics on oral haloperidol medication and correlated over 21 days with psycho pathology ...
Vaiva, G., Taret, I., Leroux, J. M., Bianchi-Decaix, I., Goudemand, M., Thomas, P., Pommery, J., Dutoit, D., Mohamed, Y., Erb, F.   +9 more
core   +1 more source

Co‐Expression of Tardive Dyskinesia and Drug‐Induced Parkinsonism in Rats Chronically Treated With Haloperidol

Neuropsychopharmacology Reports
Aim We aimed to create a rat model of drug‐induced parkinsonism and tardive dyskinesia by chronic administration of haloperidol and examine the expression of direct and indirect pathway markers in the striatum of the model rats.
Iku Kinoshita, Haruo Nishijima, Takashi Nakamura, Tomoya Kon, Shuji Shimoyama, Hiroki Hikichi, Chieko Suzuki, Masahiko Tomiyama   +7 more
doaj   +1 more source

Droperidol versus haloperidol on postoperative nausea and vomiting: a retrospective analysis

Colombian Journal of Anesthesiology
Introduction: Butyrophenones are effective prophylactic drugs against postoperative nausea and vomiting (PONV). Our practice used droperidol for PONV prophylaxis until supply chain issues in 2020 required a substitution to haloperidol.
Maia C Young, Omolola Ajayi, Julian Naranjo, Yvette N. Martin McGrew, Darrell R Schroeder, Juraj Sprung, Toby N. Weingarten   +6 more
doaj   +1 more source

The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction

, 2017
Mikhail Sergeevich Zastrozhin,1,2 Elena Anatolievna Grishina,1 Kristina Anatolievna Ryzhikova,1 Valery Valerievich Smirnov,3 Ludmila Mikhailovna Savchenko,1 Evgeny Alekseevich Bryun,1,2 Dmitry Alekseevich Sychev1 1Russian Medical Academy of Continuous ...
Smirnov VV, Ryzhikova KA, Sychev DA, Zastrozhin MS, Grishina EA, Savchenko LM, Bryun EA   +6 more
core  

Role of Haloperidol in Palliative Medicine

, 2011
Haloperidol is a butyrophenone neuroleptic agent characterized as a high-affinity dopamine antagonist, originally used for the treatment of schizophrenia. Awareness of the role dopamine plays in many symptoms in palliative care, such as nausea, vomiting,
Eric Prommer
core   +1 more source

Mitochondria‐Targeted Nanotherapies in Aging Neurodegenerative Disorders: Emerging Prospects and Clinical Potential

Advanced Healthcare Materials, Volume 15, Issue 36, 25 September 2026.
Mitochondria‐targeted nanotherapies emerge as a promising strategy for combating aging‐associated neurodegenerative disorders (NDs) by restoring mitochondrial function, reducing oxidative stress, and improving neuronal survival. Recent advances in nanotechnology, therapeutic delivery, and translational research are highlighted, providing insights into ...
Dnyandev G. Gadhave, Ashish B. Jadhav, Nitin B. Waghamode, Shubham Khot, Rajiya Khan, Ravi Hole, Shankar M. Dhobale, Manoj Aswar, Keshav Raj Paudel   +8 more
wiley   +1 more source

The correlation between CYP2D6 isoenzyme activity and haloperidol efficacy and safety profile in patients with alcohol addiction during the exacerbation of the addiction

, 2016
Dmitry Alekseevich Sychev,1 Mikhail Sergeevich Zastrozhin,1–3 Valery Valerieevich Smirnov,4 Elena Anatolievna Grishina,1 Ludmila Mikhailovna Savchenko,1 Evgeny Alekseevich Bryun1,2 1Russian Medical Academy of Postgraduate Education, Ministry of ...
Smirnov VV, Sychev DA, Zastrozhin MS, Grishina EA, Savchenko LM, Bryun EA   +5 more
core  

Delayed Recognition of Anti‐NMDAR Encephalitis Mimicking Primary Psychiatric Illness: A Case Report

Clinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT Anti‐N‐methyl‐D‐aspartate receptor (anti‐NMDAR) encephalitis frequently presents with prominent psychiatric symptoms, often mimicking primary psychiatric disorders and posing a significant diagnostic challenge. We report the case of a 33‐year‐old woman who presented with a 10‐day history of acute behavioral and psychiatric symptoms initially ...
Bhumika Ghimire, Jagat Bhatt, Saugat Niraula, Bibek Shrestha, Arun Batsa Lamsal, Shreeram Upadhyaya   +5 more
wiley   +1 more source

Haloperidol reduction can be assayed in human red blood cells

, 1989
One metabolite of haloperidol present in plasma is "reduced haloperidol." This study demonstrates that human red blood cells are capable of converting haloperidol to reduced haloperidol in vitro.
T. Inaba, T. Someya, S. W. Tang, S. W. Cheung, W. Kalow, S. Takahashi   +5 more
core   +1 more source